Article
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Blood - 15 Sept 2008
Oerlemans Ruud, Franke Niels E, Assaraf Yehuda G, Cloos Jacqueline, van Zantwijk Ina, Berkers Celia R, Scheffer George L, Debipersad Kabir, Vojtekova Katharina, Lemos Clara, van der Heijden Joost W, Ylstra Bauke, Peters Godefridus J, Kaspers Gertjan L, Dijkmans Ben A C, Scheper Rik J, Jansen Gerrit
Abstract excerpt
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in the treatment of refractory multiple myeloma. However, its clinical efficacy has been hampered by the emergence of drug-resistance phenomena, the molecular basis of which remains elusive. Toward this end, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.